CeriBell (NASDAQ:CBLL) VP David Foehr Sells 781 Shares

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 781 shares of the business’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $19.98, for a total transaction of $15,604.38. Following the sale, the vice president owned 17,550 shares in the company, valued at approximately $350,649. This trade represents a 4.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

David Foehr also recently made the following trade(s):

• On Monday, February 23rd, David Foehr sold 569 shares of CeriBell stock. The shares were sold at an average price of $19.79, for a total transaction of $11,260.51.
• On Tuesday, February 3rd, David Foehr sold 5,556 shares of CeriBell stock. The shares were sold at an average price of $20.00, for a total value of $111,120.00.
• On Monday, January 5th, David Foehr sold 5,556 shares of CeriBell stock. The stock was sold at an average price of $22.60, for a total value of $125,565.60.
• On Wednesday, December 3rd, David Foehr sold 5,265 shares of CeriBell stock. The stock was sold at an average price of $16.83, for a total transaction of $88,609.95.

CeriBell Stock Performance

NASDAQ:CBLL traded down $0.95 during mid-day trading on Wednesday, reaching $18.95. The company’s stock had a trading volume of 713,550 shares, compared to its average volume of 351,326. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12. CeriBell, Inc. has a 12-month low of $10.01 and a 12-month high of $25.98. The stock has a market cap of $703.05 million, a P/E ratio of -12.55 and a beta of 1.03. The firm’s fifty day moving average price is $21.26 and its two-hundred day moving average price is $16.17.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. The firm had revenue of $24.78 million for the quarter, compared to analysts’ expectations of $23.95 million. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%. On average, equities analysts forecast that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd lifted its holdings in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in CeriBell during the 3rd quarter valued at about $33,000. CWM LLC increased its stake in CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after purchasing an additional 1,697 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares in the last quarter. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after purchasing an additional 1,256 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on CBLL shares. Canaccord Genuity Group upped their price objective on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. BTIG Research reissued a “buy” rating and set a $30.00 price target on shares of CeriBell in a research note on Wednesday, January 28th. JPMorgan Chase & Co. dropped their target price on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Finally, TD Cowen restated a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

Key Headlines Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 beat on both EPS and revenue — CeriBell reported a loss of ($0.36) vs. consensus ($0.43) and revenue of $24.78M vs. $23.95M expectations, showing top‑line strength and a smaller-than-expected loss. Zacks: Q4 results
• Positive Sentiment: Management highlighted market expansion and revenue acceleration on the earnings call, which supports ongoing growth expectations for newborn hearing-screening adoption. Earnings call transcript
• Neutral Sentiment: FY2026 revenue guidance of $111.0M–$115.0M was issued, roughly in line with the Street estimate (~$112.7M) — guidance supports growth but isn’t a clear upside surprise. (Press release/earnings coverage.)
• Neutral Sentiment: Balance-sheet strength: very high current and quick ratios indicate ample liquidity, reducing short-term financing risk. (See filings/coverage.)
• Negative Sentiment: Insider selling: Director Josef Parvizi sold 16,714 shares (recently continued a pattern of sales), which can be viewed negatively by some investors. Insider selling report
• Negative Sentiment: Company remains unprofitable with a negative net margin (~‑63%), negative ROE, and an expected full‑year EPS loss — profitability timeline remains a key risk for valuation. Business Insider: results summary
• Negative Sentiment: Mixed analyst moves — at least one price-target cut alongside continued buy ratings elsewhere creates divergent expectations that can increase volatility. (Analyst coverage summarized in public filings/press coverage.)

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.